Specifically, MLH1 shRNA delayed xenograft formation and growth from KBP1.21 BRCA2-null cancer cells relative to wild-type controls, indicating that MLH1 may also be a useful target in established cancers. The gene discussed is BRCA2; the disease is cancer.